Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Agilent Technologies Inc Stock Research

A

110.87USD-0.03(-0.03%)Delayedas of 03 Oct 2023, 01:12 pm
Watchlist

Market Summary

USD110.87-0.03
Delayedas of 03 Oct 2023, 01:12 pm
-0.03%

A Alerts

  • 1 major insider sales recently.
  • Big fall in earnings (Y/Y)

A Stock Price

A RSI Chart

A Valuation

Market Cap

32.5B

Price/Earnings (Trailing)

28.68

Price/Sales (Trailing)

4.65

EV/EBITDA

19.35

Price/Free Cashflow

22.88

A Price/Sales (Trailing)

A Profitability

EBT Margin

23.28%

Return on Equity

23.37%

Return on Assets

12.52%

Free Cashflow Yield

4.37%

A Fundamentals

A Revenue

Revenue (TTM)

7.0B

Revenue Y/Y

-2.68%

Revenue Q/Q

-2.62%

A Earnings

Earnings (TTM)

1.1B

Earnings Y/Y

-66.26%

Earnings Q/Q

-63.25%

Price Action

52 Week Range

109.00159.59
(Low)(High)

Last 7 days

-0.9%

Last 30 days

-9.0%

Last 90 days

-7.1%

Trailing 12 Months

-8.6%

A Financial Health

Current Ratio

2.37

Debt/Equity

0.47

Debt/Cashflow

0.54

A Investor Care

Dividend Yield

0.8%

Dividend/Share (TTM)

0.89

Buy Backs (1Y)

1.68%

Diluted EPS (TTM)

3.83

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for A

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-28
Gonsalves Rodney
bought
287
111
2.59
v.p., corporate controller
2023-09-11
Binns Philip
acquired
249,159
113
2,203
senior vice president
2023-08-23
Gonsalves Rodney
sold
-415,716
118
-3,500
v.p., corporate controller
2023-08-14
Baker Jeffery C
bought
3,792
18.96
200
-
2023-07-27
McMullen Michael R.
sold
-122,720
130
-944
ceo and president
2023-07-27
McMullen Michael R.
acquired
39,761
42.12
944
ceo and president
2023-05-19
MCDONNELL PADRAIG
sold (taxes)
-22,036
128
-171
sr. vice president
2023-05-03
Ancher-Jensen Henrik
sold (taxes)
-17,789
134
-132
sr. vice president
2023-03-16
SCANGOS GEORGE A
acquired
226,848
136
1,658
-
2023-03-16
Bishop Hans Edgar
acquired
328,231
136
2,399
-

1–10 of 50

Which funds bought or sold A recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Baystate Wealth Management LLC
unchanged
-
-2,224
14,969
-%
2023-09-20
BARCLAYS PLC
added
93.37
26,248,000
64,798,000
0.04%
2023-09-19
BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL
unchanged
-
-95,334
633,718
0.26%
2023-09-13
CGC Financial Services, LLC
new
-
47,619
47,619
0.03%
2023-09-12
Farther Finance Advisors, LLC
added
25.59
5,898
70,226
0.01%
2023-09-07
ST GERMAIN D J CO INC
new
-
37,398
37,398
-%
2023-08-29
Garde Capital, Inc.
unchanged
-
-240,000
1,597,000
0.13%
2023-08-28
DT Investment Partners, LLC
unchanged
-
-8,160
73,488
0.01%
2023-08-25
Gould Capital, LLC
unchanged
-
-2,406
15,993
0.01%
2023-08-25
Brown Shipley& Co Ltd
added
14.74
-7,563
2,858,700
1.17%

1–10 of 48

Latest Funds Activity

Are funds buying A calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own A
No. of Funds

Schedule 13G FIlings of Agilent Tech

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
price t rowe associates inc /md/
2.6%
7,707,066
SC 13G/A
Feb 09, 2023
vanguard group inc
8.53%
25,250,988
SC 13G/A
Jan 26, 2023
blackrock inc.
10.9%
32,309,878
SC 13G/A
Jan 20, 2023
blackrock inc.
10.9%
32,309,878
SC 13G/A
Apr 08, 2022
blackrock inc.
10.0%
30,082,335
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
7.1%
21,689,105
SC 13G/A
Feb 09, 2022
vanguard group inc
8.04%
24,269,735
SC 13G/A
Feb 03, 2022
blackrock inc.
9.7%
29,352,219
SC 13G/A
Feb 16, 2021
price t rowe associates inc /md/
7.6%
23,512,823
SC 13G/A
Feb 10, 2021
vanguard group inc
7.76%
23,804,938
SC 13G/A

Recent SEC filings of Agilent Tech

View All Filings
Date Filed Form Type Document
Sep 29, 2023
4
Insider Trading
Sep 13, 2023
4
Insider Trading
Sep 13, 2023
3
Insider Trading
Sep 05, 2023
8-K
Current Report
Aug 31, 2023
10-Q
Quarterly Report
Aug 25, 2023
4
Insider Trading
Aug 23, 2023
144
Notice of Insider Sale Intent
Aug 15, 2023
8-K
Current Report
Jul 31, 2023
4
Insider Trading
Jul 27, 2023
144
Notice of Insider Sale Intent

A Fair Value

Loading...

Peers (Alternatives to Agilent Tech)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
32.5B
7.0B
-9.03% -8.60%
28.68
4.65
5.03% -14.68%
23.8B
4.0B
-11.06% 0.30%
26.75
6.01
2.30% 16.37%
21.6B
4.5B
-19.01% -28.49%
-5.15
4.83
-4.92% -21931.58%
16.1B
2.8B
-15.95% -22.45%
19.74
5.69
-24.31% 21.35%
16.0B
3.0B
-3.74% 0.37%
23.68
5.34
3.16% -3.93%
MID-CAP
SMALL-CAP
2.0B
146.1M
-29.45% 38.67%
-6.32
13.8
4.72% -55.19%
1.0B
112.0M
-0.96% 142.38%
-15.25
8.96
0.83% 16.42%
750.7M
189.6M
-23.79% -27.11%
-3.93
3.96
18.74% 17.75%
181.9M
114.1M
-3.40% 66.41%
-33.5
1.59
-5.49% -48.58%
138.2M
99.2M
10.00% -67.33%
-2.44
1.39
-26.56% -199.52%
97.4M
31.5M
-23.90% 60.11%
-0.66
3.09
35.12% -38.47%
82.9M
52.7M
-3.00% -18.00%
-10.98
1.57
2.10% -1984.29%
72.7M
143.9M
-40.58% -88.02%
-0.44
0.51
0.71% -18.99%
61.1M
67.1M
-31.89% -57.58%
-0.55
0.91
-12.13% -17.68%

Agilent Tech News

Benzinga
High Resolution Semiconductor ICP-MS System Market 2023 ....
Benzinga,
7 hours ago
Investor's Business Daily
Investor's Business Daily
Medical Device Network
Leading medical companies in the robotics theme.
Medical Device Network,
10 months ago
Medical Device Network
Medical Device Network
Leading medical companies in the genomics theme.
Medical Device Network,
10 months ago

Returns for A

Cumulative Returns on A

12.3%


10-Year Cumulative Returns

13.8%


7-Year Cumulative Returns

9.6%


5-Year Cumulative Returns

3.9%


3-Year Cumulative Returns

Risks for A

What is the probability of a big loss on A?

47.3%


Probability that Agilent Tech stock will be more than 20% underwater in next one year

11.5%


Probability that Agilent Tech stock will be more than 30% underwater in next one year.

0%


Probability that Agilent Tech stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does A drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Agilent Tech was unfortunately bought at previous high price.

Drawdowns

Financials for Agilent Tech

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-0.7%6,9947,0406,9306,8486,6596,5276,4456,3196,1425,8175,5305,3395,2235,2365,2365,1635,0905,0194,9874,9144,809
Cost Of Revenue---------------------2,184
Costs and Expenses4.3%5,5815,3495,2625,2305,1175,0605,0504,9724,8914,6724,5714,4934,4264,4444,3304,2224,1554,0884,0624,0103,950
  S&GA Expenses-0.3%1,6631,6681,6391,6371,6041,5951,6291,6191,6171,5611,4991,4961,4941,5131,5091,4601,4351,4101,3971,3891,376
  R&D Expenses0.4%486484473467464461455441427406494495495504406404406402395387374
EBITDA-100.0%-2,0211,9851,9051,9071,8431,7771,7621,5871,4701,3171,2281,1781,1581,229------
EBITDA Margin-100.0%-0.29*0.29*0.28*0.29*0.28*0.28*0.28*0.26*0.25*0.24*0.23*0.23*0.22*0.23*------
Interest Expenses5.5%96.0091.0088.0084.0082.0084.0083.0081.0079.0077.0077.0078.0080.0079.0076.0074.0071.0071.0073.0075.0077.00
Earnings Before Taxes-16.2%1,3741,6391,5951,5041,4971,4271,3671,3601,1951,087935842790793890919932952961946928
EBT Margin-100.0%-0.23*0.23*0.22*0.22*0.22*0.21*0.22*0.19*0.19*0.17*0.16*0.15*0.15*0.17*------
Net Income-16.1%1,1331,3511,3231,2541,3281,2631,2051,2109909258107196916837641,0711,0721,1171,140316298
Net Income Margin-100.0%-0.19*0.19*0.18*0.20*0.19*0.19*0.19*0.16*0.16*0.15*0.13*0.13*0.13*0.15*------
Free Cashflow-100.0%-1,1831,0611,0211,0221,0581,2801,2971,2681,2531,092802736666599------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-1.1%10,67510,79210,91910,53210,48410,45510,32710,70510,49110,3989,6749,6279,5469,4559,5019,4528,6259,0228,9528,5588,349
  Current Assets2.1%4,0303,9494,0783,7783,6903,6433,4743,7993,6323,5143,4833,4153,2453,1713,1023,1893,4573,8123,7123,8483,667
    Cash Equivalents13.1%1,3291,1751,2501,0531,0731,1881,1161,4901,4351,3871,3361,4411,3641,3291,2321,3881,7712,1612,0642,2542,139
  Inventory-2.8%1,0721,1031,1111,0381,010937879830818791755720746750706679660657653638623
  Net PPE2.3%1,2111,1841,1471,1001,0541,010974945905884866845846836844850839827829822801
  Goodwill0.1%3,9843,9803,9833,9523,9483,9563,9643,9753,9764,0543,6183,6023,6063,5823,5893,5933,1073,1123,1332,9732,933
Liabilities2.1%5,1175,0115,3105,2275,3935,3335,1735,3165,5455,5884,8704,7544,5654,6874,6534,7043,8783,8973,9163,9613,781
  Current Liabilities5.6%1,7601,6661,9361,8611,9021,8131,5841,7081,7241,7581,6871,4671,3141,9451,8922,0801,6221,1181,0951,1711,014
  Short Term Borrowings-55.00-23836.00180175--13020531475.0040.00700675616504----
  Long Term Debt0.0%2,7342,7332,7332,7332,732--2,729-------------
    LT Debt, Non Current------2,7302,7302,7292,7282,7272,1852,2842,2831,7881,7871,7911,2941,7981,7981,7991,799
Shareholder's Equity-3.9%5,5585,7815,6095,3055,0915,1225,1545,3894,9464,8104,8044,8734,9814,7684,8484,7484,7475,1255,0364,5714,568
  Retained Earnings-36.6%44470054132413916015934890.00-12.004.0081.0013015.0073.00-18.00-12217890.00-336-416
  Additional Paid-In Capital0.4%5,3825,3605,3455,3255,3115,2925,2905,3205,3075,2715,2665,3115,3245,2885,2935,2775,2705,3435,3245,3085,312
Shares Outstanding-0.7%293295296295298299301302303304306306309309310309312317318318320
Minority Interest--------------------4.004.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations16.1%1,7041,4681,3531,3121,3051,3131,5021,4851,4211,3771,2189218588107491,0211,0791,0341,0851,0871,003
  Share Based Compensation0.8%12312212512512111511411010810596.0083.0078.0076.0075.0072.0071.0067.0063.0070.0068.00
Cashflow From Investing-4.4%-380-364-363-338-287-275-786-749-717-688-154-147-1,313-1,332-1,335-1,590-511-933-928-705-650
Cashflow From Financing3.6%-1,070-1,110-843-1,372-1,355-1,215-926-696-641-650-972-71749.00-302-238-299-927-934-956-797-772
  Dividend Payments----250---236---222---206---191-
  Buy Backs1.9%6306187671,1391,140930891788902822753469268784708723760454450422336

A Income Statement

2023-07-31
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Jul. 31, 2023
Jul. 31, 2022
Net revenue:    
Net revenue$ 1,672$ 1,718$ 5,145$ 4,999
Costs and expenses:    
Cost of revenue1,0147792,5952,289
Research and development118116367348
Selling, general and administrative4074121,2411,215
Total costs and expenses1,5391,3074,2033,852
Income from operations1334119421,147
Interest income132344
Interest expense(24)(19)(73)(61)
Other income (expense), net10316(41)
Income before taxes1323979191,049
Provision for income taxes2168154163
Net income$ 111$ 329$ 765$ 886
Net income per share    
Basic$ 0.38$ 1.10$ 2.59$ 2.95
Diluted$ 0.38$ 1.10$ 2.58$ 2.94
Weighted average shares used in computing net income per share:    
Basic294298295300
Diluted295299296301
Product    
Net revenue:    
Net revenue$ 1,222$ 1,306$ 3,819$ 3,773
Costs and expenses:    
Cost of revenue7845581,8901,633
Service and Other    
Net revenue:    
Net revenue4504121,3261,226
Costs and expenses:    
Cost of revenue$ 230$ 221$ 705$ 656

A Balance Sheet

2023-07-31
CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) - USD ($)
$ in Millions
Jul. 31, 2023
Oct. 31, 2022
Current assets:  
Cash and cash equivalents$ 1,329$ 1,053
Accounts receivable, net1,3391,405
Inventory1,0721,038
Other current assets290282
Total current assets4,0303,778
Property, plant and equipment, net1,2111,100
Goodwill3,9843,952
Other intangible assets, net502821
Long-term investments190195
Other assets758686
Total assets10,67510,532
Current liabilities:  
Accounts payable452580
Employee compensation and benefits331455
Deferred revenue512461
Short-term debt5536
Other accrued liabilities410329
Total current liabilities1,7601,861
Long-term debt2,7342,733
Retirement and post-retirement benefits9297
Other long-term liabilities531536
Total liabilities5,1175,227
Commitments and Contingencies (Note 9 and 12)
Stockholders' equity:  
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding at July 31, 2023 and October 31, 202200
Common stock; $0.01 par value; 2 billion shares authorized; 293 million shares at July 31, 2023 and 295 million shares at October 31, 2022, issued and outstanding33
Additional paid-in-capital5,3825,325
Retained earnings444324
Accumulated other comprehensive loss(271)(347)
Total stockholder's equity5,5585,305
Total liabilities and equity$ 10,675$ 10,532
Michael R. McMullen
17000
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.